Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation

Transplantation

Volumn 80, Issue 9, 2005, Pages 1186-1193

  Lerut, Jan ^a   Van Thuyne, Vincent ^a   Mathijs, Jules ^a   Lemaire, Julien ^a   Talpe, Stéphanie ^a   Roggen, Francine ^a   Ciccarelli, Olga ^a   Zuckermann, Michele ^a   Goffette, Pierre ^a   Hope, James ^b   Gianello, Pierre ^a   Bazin, Hervé ^a   Cornet, Anne ^a   Rahier, Jacques ^a   Latinne, Dominique ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b BioTransplant Inc   (United States)

Author keywords

Adhesion molecule; Costimulation blockade; Immunology; Liver transplantation; Monoclonal antibody

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOSPORIN A; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; IMMUNOSUPPRESSIVE AGENT; MEPREDNISONE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; ESOPHAGUS CANCER; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOLOGY; INCIDENCE; KIDNEY DYSFUNCTION; LIVER DISEASE; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MALE; METASTASIS; MYCOSIS; NONHUMAN; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SAFETY; SURVIVAL RATE; TIME SERIES ANALYSIS; UTERINE CERVIX CANCER; VIRUS INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFECTION; LIVER FAILURE; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; MIDDLE AGED; NEOPLASMS; POSTOPERATIVE PERIOD; STEROIDS; SURVIVAL ANALYSIS; TACROLIMUS;

EID: 28544446958     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000173996.81192.F9     Document Type: Article

References (30)

1. Starzl TE, Demetris JA. Liver Transplantation. Chicago, 1994.
2. + human T cells in vitro. Int Immunol 1996; 8: 1113.
3. Lerut J, Ciccarelli O, Roggen F, et al. Adult liver transplantation: the Université catholique de Louvain experience. In: Terasaki P, Cecka J, eds. Clinical Transplants. 2000.
4. Demetris AJ, Batts KP, Dhillon AP, et al. International panel comprised of Banff scheme for grading liver allograft rejection an international consensus document. Hepatology 1997; 25: 658.
5. Lerut J, Talpe S, Van Thuyne V, et al. The "seven-up" score in adult liver transplantation: an easy tool to define the real need for allograft rejection treatment [abstract]. 10th Congress ESOT, Lisboa, 2001.
6. Nizet Y, Chentoufi AA, de la Parra B, et al. The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, Lo-CD2a/BTI-322. Transplantation 2000; 69: 1420.
7. Mourad M, Besse T, Malaise J, et al. BTI-322 for acute rejection after renal transplantation. Transplant Proc 1997; 29: 2353.
8. Besse T, Malaise J, Mourad M, et al. Prevention of rejection with BTI-322 after renal transplantation. Transplant Proc 1997; 29: 2435.
9. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000; 11: S1.
10. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath IH and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
11. Lerut J, Mathijs J, Lemaire J, et al. Tacrolimus monotherapy in adult liver transplantation: preliminary results of a prospective, randomized, double-blind, placebo-controlled, single- center study. [Abstract 446] Transplantation 2002; S74:155.
12. Lerut I. Avoiding steroids in solid organ transplantation. Transpl Int 2003; 16: 213.
13. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502.
14. Chan C, Lechler RI, George AJT. Tolerance mechanisms and recent progress. Transplant Proc 2004; 36: 561S.
15. Starzl TE, Zinkernagel RM. Transplantation tolerance from a historical perspective. Nature Rev Immunol 2001; 1: 233.
16. Dallmann MJ. Immunobiology of graft rejection. In: Ginns AB, Cosimi PJ, Morris PJ, eds. Transplantation. Boston: Blackwell Science, 1998.
17. Weckerle Th, Kurtz J, Bigenzahn S, et al. Mechanisms of transplant tolerance induction using co-stimulatory blockade. Organ Transplant 2002; 14: 592.
18. Mandelbrot DA, Sayegh MH. Role of novel T-cell co-stimulatory pathways in transplantation. Organ Transplant 2003; 8: 25.
19. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 1.
20. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allograft after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
21. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4 Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci 1997; 94: 8789.
22. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD 154 prevents acute renal rejection in non human primates. Nat Med 1999; 5: 686.
23. Qin L, Chavin KD, Lin J, et al. Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergized to prolong allograft survival. J Exp Med 1994; 179: 341.
24. Cho CS, Burkly LC, Fechner JH, et al. Successful conversion from conventional immunosuppression anti-CD 154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipient. Transplantation 2001; 72: 587.
25. Hourmant M, Bedrossian J, Durand D, et al. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation 1996; 62: 1565.
26. Boussiotis VA, Freeman GJ, Griffin JD, et al. CD2 is involved in maintenance and reversal of human alloantigen-specitic clonal anergy. J Exp Med 1994; 180: 1665.
27. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340: 1704.
28. Haug CE, Colvin RB, Delmonico FL, et al. A phase I trial of immunosuppression with anti-ICAM-1 mAb in renal allograft recipients. Transplantation 1993; 55: 766.
29. Le Moine A, Goldman M. Non-classical pathways of cell-mediated allograft rejection: new challenges for tolerance induction. Am J Transplant 2003; 3: 101.
30. Izawa A, Sayegh MH, Chandrakar A. The antagonism of calcineurin inhibitors and costimulatory blockers: fact or fiction. Transplant Proc 2004; 36: 570S.